Expectations For Adobe’s Q2 Results Are ‘Depressed’: JPMorgan
Adobe stock has been on a downtrend since its previous quarter results. Expectations for the quarter remains low, reflecting concerns around monetizing AI.
How May’s Inflation Slowdown Could Influence Fed’s Next Move: Insights From 6 Economists
Inflation data showed a bigger slowdown than expected, easing concerns about high interest rates before the June FOMC meeting.
Apple, Nvidia, Or Microsoft, Who Will Reach $4 Trillion Valuation First? Top Analyst Lays Out Bull Thesis For Tim Cook’s Company, Predicts Potential 270M iPhone Upgrades
Apart from Apple, Microsoft and Nvidia are the two other frontrunners in the race to $4 trillion market capitalization, according to him.
Apple Analyst Says ‘You Don’t Wanna Be Anywhere Near The Stock’ In 4 Years, Feels WWDC Was Like A ‘Snap CEO Talking Like We’re Gonna Target 22-Year Olds’
Following Tim Cook's keynote speech, the consensus estimates remain unchanged, said Needham analyst Laura Martin in an interview with Yahoo Finance.
All The Tesla CEO’s Men (And Women): Elon Musk’s Inner Circle Lobbies Hard For His Pay Plan Ahead Of Crucial Board Meet
Musk has hinted that a rejection could lead to him scaling back his involvement with the company, potentially spooking investors.
Citigroup Analyst Sees Limited Near-Term Upside For American Express Despite Positive Long-Term Outlook – Here’s Why
Citigroup analyst initiates coverage of American Express with Neutral rating and $250 price target. Strong management, but limited near-term upside.
JP Morgan Downgrades Cleveland-Cliffs: Rising Capex And Modest Auto Demand Hamper Growth Prospects
CLF stock downgraded by JP Morgan to Neutral with lower price target. Reduced price forecasts, weak EV demand, but strong long-term prospects.
AI Will Save Time, Revolutionize Advertising, Says Cathie Wood’s ARK Invest Report
Enthusiasm over AI has boosted Invesco QQQ ETF's returns. ARK Invest's report predicts faster consumer AI adoption, $9 trillion in consumption, and advertising opportunities.
Eli Lilly’s Donanemab Gains Favorable FDA Advisory Verdict, Boosting Stock Potential, Says BofA Analyst
Eli Lilly's donanemab for Alzheimer's disease garners positive FDA committee verdict, prompting analyst's bullish outlook amid comparisons to Biogen's Leqembi.
What’s Going On With Iris Energy Stock?
Iris Energy Limited (NASDAQ:IREN) shares are trading higher Tuesday after Cantor Fitzgerald analyst Brett Knoblauch assumed Iris Energy with an Overweight rating and a price target of $23, up from a prior target of $10.
The Details: